The classical activity of telomerase (TERT) is to maintain telomere homeostasis, 20 ensuring chromosome stability and cellular proliferation. However, increasing 21 evidences of telomere-independent human TERT functions have been lastly obtained. 22 We report here that TERT directly binds to the TCF binding elements (TBE) located 23 upstream the oncomiR MIR500A inducing its expression and promoting cancer 24 invasiveness. This function is independent of telomerase activity, since catalytic 25 inactive TERT also induces MIR500A expression and telomerase inhibitors directed 26 2 against TERT, but not to its RNA component TERC, inhibit telomerase-induced 27 MIR500A expression and cancer invasiveness. Mechanistically, telomerase-induced 28 MIR500A down-regulates key genes of the Hedgehog signaling pathway, namely 29 patched 1 (PTCH1), Gli family zinc finger 3 (GLI3) and cullin 3 (CUL3), increasing 30 tumor invasiveness. Our results show a crucial role of the TERT/MIR500A/Hedgehog 31 axis is tumor aggressiveness, pointing out to the relevance of inhibiting the 32 extracurricular functions of telomerase to fight cancer.
Introduction
Human telomerase (TERT) is reactivated in approximately 90% of all cancers while, in approximately 10% of tumor, telomere length is maintained independently of did not affect that of MIR532 (Fig. 3B) , which is located upstream and TERT is unable 141 to bind its TBE.
142
MIR500A mediates TERT-increased invasiveness of tumor cells 143 We next examined whether the different components of the cluster are also 144 implicated in TERT-mediated tumor invasion. To achieve this goal, we overexpressed 145 several miRNAs in parental and TERT-expressing SAOS 2 cells by transient 146 transfection with the correspondent pre-MIR ( Fig. S4) and studied the effect on the in 147 vivo invasive capacity cells (Fig. 4) . Surprisingly, MIR500A was the only one able to 148 increase the in vivo invasion capacity of tumor cells, while the MIR532, which is not 149 regulated by TERT, inhibited invasiveness of parental tumor cells ( Figs. 4B, 4D) . 150 Collectively, these results show that MIR500A mediated TERT-induced tumor 151 invasiveness.
152
The regulation of MIR500A by TERT does not depend on telomerase activity 153 To ascertain whether TERT requires its telomerase activity to regulate the 154 expression of MIR500A, we used a dominant-negative mutant of TERT (DN-TERT), 155 which has two point mutations in the A motif at the RT domain that cause it to lack the 156 enzymatic activity (17). DN-TERT was expressed at the same levels than wild type 157 TERT ( Fig. 5A) and also increased MIR500A promoter activity ( Fig. 5B) , MIR500A 158 transcript levels ( Fig. 5C ) and tumor invasiveness in vivo ( Fig. 5D) , in a similar level 159 than TERT. To further confirm the novel non-canonical role of TERT, we used two 160 different telomerase inhibitors: BIBR 1532, that binds and blocks TERT (18) and TAG 161 6, that binds and blocks TERC (19). Although both drugs were able to inhibit 162 telomerase activity ( Fig. S5A) , only BIBR 1532 decreased both the expression of 163 MIR500A (Fig. 5E ) and the tumor invasiveness in vivo (Fig. 5F) . As expected, and to 164 discard any off-target effect, the treatment of parental SAOS 2 cells with these drugs did 165 not affect either the expression of MIR500A (Fig. S5B) or the tumor invasiveness in 166 vivo (Fig. S5C) . 167 Hedgehog signaling pathway is regulated by MIR500A
168
The Target Scan software (https://www.targetscan.org) revealed that the 3'UTR 169 of 3253 human genes contain putative target sites for MIR500A. By using the MetaCore 170 7 software (https://www.omictools.com/metacore-tool), we classified the signaling 171 pathways enriched in the predicted targets of MIR500A and found crucial role involved 172 in cancer aggressiveness, such as Notch, WNT and Hedgehog signaling pathways (Fig   173   S6 ). We focused in the latter, since PTCH1, GLI3 and CUL3 have all a putative target 174 site for MIR500A ( Fig. 6A) . We confirmed by real-time RT-qPCR that PTCH1, GLI3 175 and CUL3 were all down-regulated in TERT-overexpression conditions (Figs. 6B-6D, 176 S7A). In addition, MIR500A directly bound to PTCH1 3'UTR, as assayed by luciferase 177 reporter experiments (Figs. 6E, S7B ). 178 The above results prompted us to analyze if there is a correlation among TERT,
179
MIR500A and PTCH1 expression in cancer. We observed a significant positive 
213
The regulation of miRNAs is poorly understood, due in part to the difficulty in 214 predicting promoters from short conserved sequences. We localized MIR500A in a 215 cluster of 8 miRNAs: MIR532, MIR118, MIR500A, MIR362, MIR501, MIR500B, 216 MIR660 and MIR502. This cluster is into the short arm of the X chromosome 217 (Xp11.23), in the intron 3 of the CLCN5 gene. A few studies indicate that intronic 218 miRNAs are not necessarily co-transcribed with their host gene, which suggests that 219 they might have their own independent intronic promoters (23). Our results showed that 220 the expression of CLCN5 is not affected by the presence of TERT, which indicates that 221 the regulation of MIR500A by TERT is not mediated through the regulation of its host 222 gene promoter. As it has been reported that TERT directly interacts with TBE-223 containing promoters (3, 4), we decided to analyze the MIR500A upstream sequence.
224
Notably, the sequence analysis revealed the presence of various TBE sequences 225 upstream of MIR500A and MIR532. We found that TERT was able to increase the 
288
By using the data generated by the TCGA Research Network, we have found a 289 strong positive correlation between TERT and MIR500A, while MIR500A expression 290 was found to be negatively correlated with that of PTCH1 in stomach adenocarcinoma 291 and bladder urothelial carcinoma. A high-stage of gastric cancer and negative PTCH1 292 staining have been identified as unfavorable risk factor for overall survival (438) and it 293 has been described an important role of Hh signaling in bladder cancer growth and 294 tumorigenicity (39). In addition, Shh signaling crosstalks with other signaling pathways 295 during development and cancer progression, such as Notch, Wnt, and TGF- signaling 296 pathways (40), which are also regulated by MIR500A (26) and TERT (6). Therefore, our 297 results support that the MIR500A is also a good therapeutic target to fight cancer.
298
In summary, we have demonstrated for the first time that TERT is able to regulate 299 the expression of specific microRNAs through its direct binding to TBE regions at their 300 promoter sequence. In particular, TERT-mediated up-regulation of MIR500A results in a 301 post-transcriptionally repressesion of PTCH1, which triggers a ligand-independent 302 aberrant Hh signaling activation that significantly increases tumor cell invasiveness in a 303 zebrafish xenograft model (Fig. 7) . This is a novel non-canonical telomerase function, TERT binds directly to the TBE sequences located at the promoter region of MIR500A, resulting in the up-regulation of MIR500A and also the miRNAs located downstream it. As a compensatory mechanism, this regulation is fine-tuned by the MIR532, which acts as a negative regulator by repressing the hTERT mRNA. (III) The oncomiR MIR500A represses post-transcriptionally the mRNA of the tumor suppressor PTCH1, triggering a ligand-independent aberrant Hedgehog signaling activation (IV) that contributes significantly to increase the invasiveness of tumor cells. (V) The chemical inhibition of TERT with BIBR 1532 could be a new strategy to fight cancer.
